Back to top
more

Alkermes plc (ALKS)

(Delayed Data from NSDQ)

$22.83 USD

22.83
902,741

+0.53 (2.38%)

Updated Sep 16, 2019 03:57 PM ET

After-Market: $22.86 +0.03 (0.13%) 6:12 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.58%
17.73%
9.37%
4.95%
1.76%
10.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

D Value | C Growth | C Momentum | D VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Why Is Alkermes (ALKS) Down 3.9% Since Last Earnings Report?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALKS

Zacks Equity Research

Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down

Clovis (CLVS) reports dismal second-quarter 2019 results. The company provides lower-than-expected guidance for product sales in 2019.

BMY CLVS ALKS AXGT

Zacks Equity Research

Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates

Impressive second-quarter results by most biotech bigwigs are the key highlights of the week. Most companies also increase their annual guidance.

BMY AMGN GILD ALKS CELG LXRX

Zacks Equity Research

Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2

Alkermes (ALKS) surpasses earnings and sales estimates in the second quarter of 2019.

ALNY ALKS ACOR BIIB

Zacks Equity Research

Alkermes (ALKS) Beats Q2 Earnings and Revenue Estimates

Alkermes (ALKS) delivered earnings and revenue surprises of 190.00% and 10.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ALKS

Zacks Equity Research

Earnings Preview: Alkermes (ALKS) Q2 Earnings Expected to Decline

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALKS

Zacks Equity Research

Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study

Key highlights of the past week include collaborations and other pipeline updates.

HOOK ALKS EXEL GILD AMGN GLPG

Zacks Equity Research

ALXN or ALKS: Which Is the Better Value Stock Right Now?

ALXN vs. ALKS: Which Stock Is the Better Value Option?

ALXN ALKS

Zacks Equity Research

Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA

Alkermes (ALKS) plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia.

AZN LLY AGN ALKS

Zacks Equity Research

CBM vs. ALKS: Which Stock Should Value Investors Buy Now?

CBM vs. ALKS: Which Stock Is the Better Value Option?

CBM ALKS

Zacks Equity Research

Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230

Alkermes (ALKS) initiates monotherapy expansion phase of ALKS 4230 to treat patients with renal cell carcinoma or melanoma.

MRK AGTC ALKS ANIK

Zacks Equity Research

CBM vs. ALKS: Which Stock Should Value Investors Buy Now?

CBM vs. ALKS: Which Stock Is the Better Value Option?

CBM ALKS

Zacks Equity Research

Biogen Reports Interim Phase III Data on Diroximel Fumarate

Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.

NVS ALKS BIIB TEVA

Zacks Equity Research

Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression

Allergan's (AGN) sNDA for Vraylar gets the FDA approval for the treatment of adult patients with major depressive episodes related to bipolar I disorder.

JNJ AGN AZN ALKS

Zacks Equity Research

Why Is Alkermes (ALKS) Down 21% Since Last Earnings Report?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALKS

Zacks Equity Research

ALXN or ALKS: Which Is the Better Value Stock Right Now?

ALXN vs. ALKS: Which Stock Is the Better Value Option?

ALXN ALKS

Zacks Equity Research

Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1

Alkermes (ALKS) reports narrower-than-expected loss and sales beat in the first quarter of 2019.

JNJ MRK BIIB ALKS

Zacks Equity Research

GILD vs. ALKS: Which Stock Is the Better Value Option?

GILD vs. ALKS: Which Stock Is the Better Value Option?

GILD ALKS

Zacks Equity Research

Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALKS

Zacks Equity Research

Alkermes Reports Positive Data From Schizophrenia Study

Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.

AGN JNJ AZN ALKS

Zacks Equity Research

Recro Pharma Falls as FDA Denies Approval to Pain Candidate

FDA issues complete response letter for Recro Pharma's (REPH) marketing application for pain candidate, meloxicam, for the second time.

ALKS OCUL REPH AITB

Zacks Equity Research

Alkermes Focuses on Pipeline, Depends on Partners for Funds

Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.

LLY JNJ BIIB ALKS

Zacks Equity Research

Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALKS

Zacks Equity Research

Allergan's Depression Candidate Fails in Studies, Stock Down

Allergan's (AGN) three acute pivotal studies on depression candidate, rapastinel, fail to meet their primary endpoint. Stocks declines 1.9%

AGN LLY JNJ ALKS

Zacks Equity Research

Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates

Key highlights of the past week are merger agreements, and regulatory and pipeline developments.

CELG VRTX REGN ALKS ONCE CMTA